Veno-occlusive disease is a liver complication of stem cell transplant in which the smallest blood vessels of the liver become blocked, usually in the first three weeks. Teams look for it every day by weighing the patient, examining the abdomen and checking blood tests, because early treatment is linked with better survival. The medicine used is defibrotide, given with careful fluid management.
The reader's own unit's policy comes first. Before transplant, assess risk factors and address those that can be changed (BCSH/BSBMT 2013, 1A); ursodeoxycholic acid from conditioning to day +90 is recommended by EBMT for adults (2020) and suggested by BCSH/BSBMT (2C). Heparin, prostaglandin E1, pentoxifylline and antithrombin are not advised for prevention. Monitor weight, abdominal girth, liver size, bilirubin, creatinine and platelet transfusion need daily through the risk period, with baseline imaging in children. Diagnosis: BCSH/BSBMT 2013 uses the modified Seattle or Baltimore criteria (1A); EBMT adult criteria (2016, refined 2023) require bilirubin of 2 mg/dL or more with two of painful hepatomegaly, weight gain over 5% and ascites for clinical disease in the first 21 days, add late-onset disease and a 'probable' category (any two of five signs including imaging); EBMT paediatric criteria (2018) set no time limit and no mandatory bilirubin and count transfusion-refractory thrombocytopenia. Grade severity (EBMT: mild, moderate, severe, very severe). Defibrotide 6.25 mg/kg every 6 hours for at least 21 days is the only licensed treatment (EBMT Handbook): the US label covers disease with renal or pulmonary dysfunction and sets a maximum of 60 days, the European label covers severe disease; EBMT advises starting promptly in severe and very severe disease and early in moderate disease; BCSH/BSBMT recommends it for treatment (1B). The US label contraindicates systemic anticoagulants and fibrinolytics with it, says not to start it during active bleeding, and says to stop the infusion at least 2 hours before an invasive procedure; the European label contraindicates thrombolytics and does not recommend other medicines that raise bleeding risk. Supportive care: cautious fluid and sodium balance, daily creatinine, intake and output, twice-daily weights, enteral rather than parenteral nutrition, and EBMT advises a platelet transfusion threshold of 30 thousand million per litre during defibrotide. Involve critical care and hepatology early (1C). On defibrotide for prevention the sources disagree: a 2023 randomised trial found no benefit and the European Medicines Agency says it is not to be used for prophylaxis, while EBMT's 2026 paediatric consensus supports it in high-risk children. All positions are shown under variants.
Why: EBMT lists, among others, existing liver disease, a second transplant, earlier gemtuzumab ozogamicin or inotuzumab ozogamicin, iron overload and myeloablative conditioning as risk factors; it suggests delaying the transplant where feasible until iron overload or acute hepatitis has been treated, and adjusting the conditioning.
“It is recommended that patients are assessed for risk factors for VOD (SOS) and that these risk factors are addressed prior to haematopoietic stem cell transplantation (1A).”
Why: EBMT lists liver-toxic medicines among the risk factors, so anything else that strains the liver is removed if it safely can be.
“Furthermore, hepatotoxic drugs should be discontinued whenever possible”
Why: Many children already have a large liver or some fluid before transplant, so later changes can only be judged against their own starting point. The 2018 criteria word this as suggested; the 2024 EBMT Handbook says a pretransplant ultrasound is recommended.
“Suggested: imaging (US, CT or MRI) immediately before HCT to determine baseline value for both hepatomegaly and ascites.”
Why: In three pooled trials it reduced the proportion of people who developed the liver complication. The EBMT statement quoted is written for adults; the British guideline suggests ursodeoxycholic acid without giving a schedule in its abstract (2C).
“Therefore, the use of ursodeoxycholic acid is recommended from the beginning of the conditioning until day 90 after transplantation.”
Why: EBMT found no convincing evidence that any of them prevents it and notes bleeding in the heparin studies; the British guideline cites toxicity for heparin and prostaglandin E1.
“Therefore, given the absence of conclusive results on its effectiveness and its potential side effects, heparin should be abandoned as SOS prophylaxis.”
Why: Every set of diagnostic criteria rests on a change from baseline in weight, liver size, fluid and bilirubin, so the change can only be seen if these are measured daily.
Common practice: The adult guidelines read define the disease by weight gain above baseline, hepatomegaly, ascites and bilirubin but none states a monitoring schedule before diagnosis in a sentence that could be quoted; daily weights are universal on transplant units. The paediatric criteria speak of daily measurements (next step), and a company-funded UK Delphi consensus sets out monitoring practice (see variants).
Why: About three in ten children with the disease have no jaundice, and the paediatric criteria call platelets being used up, with at least daily transfusions, an early and sensitive sign.
“In children, daily measurements of weight and abdominal circumference may suggest the need for further investigations to assess hepatomegaly and ascites.”
Why: Waiting for every classic sign can delay treatment, so the current European criteria add a 'probable' category that lets treatment start earlier.
“Probable SOS/VOD would be defined by two or more of the following five criteria: hyperbilirubinemia, painful hepatomegaly, weight gain >5%, ascites, and/or ultrasound and/or elastography suggestive of SOS/VOD (Table 49.2).”
Why: About three in ten children with the disease have no jaundice, so criteria that insist on a raised bilirubin miss them or find them late.
“The pEBMT criteria introduced in 2018 (Table 49.5) intend to cover the pediatric particularities and trigger early therapeutic intervention.”
Why: Other liver problems after a transplant, such as infection, graft-versus-host disease and drug injury, can look similar. The guideline says ultrasound may be helpful (1C) and recommends the route through the neck vein to reduce the risks of the biopsy (1C).
“It is recommended that liver biopsy be reserved for patients in whom the diagnosis of VOD (SOS) is unclear and there is a need to exclude other diagnoses (1C).”
Why: Severity decides how urgently treatment starts; dysfunction of two or more organs places the person in the highest grade, and two or more risk factors move a mild or moderate case up a grade.
“According to the EBMT, SOS/VOD is graded in four stages of severity: mild, moderate, severe, and very severe, based on the following parameters: time since the first clinical manifestation of SOS/VOD, bilirubin level and kinetics, transaminase level, weight gain, and renal function (Table 49.3).”
Why: EBMT calls defibrotide the only agent with proven efficacy for severe and very severe disease, and in expanded-access programmes people who started it sooner after diagnosis were more likely to be alive at day 100. The statement is written for adults; the Handbook says early treatment matters in children too.
“Given the mortality associated with severe and very severe SOS/VOD, it is mandatory to treat these patients promptly, and DF should be initiated as soon as possible.”
Why: This is the dose and length of treatment in the US label, for adults and children. The European label gives the same dose for at least 21 days and until the signs resolve, with no stated maximum. EBMT notes that higher doses seem to add side effects without added benefit, and advises using corrected body weight in people with obesity.
“Administer DEFITELIO for a minimum of 21 days. If after 21 days signs and symptoms of hepatic VOD have not resolved, continue DEFITELIO until resolution of VOD or up to a maximum of 60 days.”
Jazz Pharmaceuticals (industry), on DailyMed, US National Library of Medicine 2025 · Prescribing information, section 2.1
Why: The US label says defibrotide may increase the risk of bleeding and has no known reversal agent; its warning does not count use for routine maintenance or reopening of central venous lines. Of these medicines the European label contraindicates only clot-dissolving drugs, and says systemic anticoagulants need careful monitoring and are not recommended.
“There is no known reversal agent for the profibrinolytic effects of DEFITELIO. Discontinue DEFITELIO infusion at least 2 hours prior to an invasive procedure.”
Jazz Pharmaceuticals (industry), on DailyMed, US National Library of Medicine 2025 · Prescribing information, sections 2.3, 4 and 5.1
Why: The disease causes fluid retention and can bring kidney failure with it, so EBMT recommends cautious fluid and sodium balance with close watch on the kidneys.
“Importantly, renal function must be closely monitored with daily creatinine assessment, monitoring of ingesta-excreta, and twice daily weight measurement.”
Why: Nutrition through a vein adds fluid, infection risk and further strain on the liver.
“Parenteral nutrition is associated with fluid overload, infectious complications, and hepatotoxicity, and should be avoided.”
Why: People with failure of several organs are generally moved to intensive care, and a liver unit can advise on options such as a shunt or a liver transplant, which the guideline says may be considered. EBMT says a shunt helps symptoms only, with no benefit on survival.
“Early discussion with critical care specialists and a specialist hepatology unit is recommended in the management of VOD (SOS) and other treatment options including transjugular intrahepatic portosystemic shunt or hepatic transplantation may be considered (1C).”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Two bodies have written guidance and they differ in places; both are shown. The British guideline (BCSH/BSBMT 2013) is the only one read that grades its recommendations, and it is the older: it bases diagnosis on the modified Seattle or Baltimore criteria (1A), recommends defibrotide for treatment (1B) and judicious fluid management (1C). EBMT has since issued adult criteria (2016, refined in 2023 with probable, clinical and proven categories and a severity grade), paediatric criteria (2018) and a treatment position statement (2020); these are expert consensus without grades, written with educational grants from the maker of defibrotide or by authors who declared honoraria from it, and the criteria were written to allow earlier diagnosis. On treatment both bodies and both labels support defibrotide; EBMT and the European label give the dose as 25 mg/kg a day, in four doses of 6.25 mg/kg as in the US label, and EBMT calls it the only agent with proven efficacy; they differ on whom to treat (the US label names disease with renal or pulmonary dysfunction, the European label severe disease, EBMT adds moderate disease) and on defibrotide for prevention, where the British 2013 recommendation predates a 2023 randomised trial that found no benefit and a 2022 European Medicines Agency communication that it is not to be used for prophylaxis. Ursodeoxycholic acid for prevention is recommended by EBMT and suggested by BCSH/BSBMT (2C).
British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 · EBMT task force (Bone Marrow Transplantation, Mohty et al.). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) 2020 · EBMT (Bone Marrow Transplantation, Mohty et al.). All authors declared honoraria or research support from Jazz Pharmaceuticals (industry) 2023 · EBMT (Bone Marrow Transplantation, Corbacioglu et al.). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry); all authors declared honoraria or research support from Jazz 2018 · EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024 · Jazz Pharmaceuticals (industry), on DailyMed, US National Library of Medicine 2025 · European Medicines Agency; the communication is issued by the marketing authorisation holder (industry) in agreement with the Agency 2023 · The Lancet Haematology (Grupp et al.). Funded by Jazz Pharmaceuticals (industry). Two corrections were published in 2023 2023
Where it differs: BCSH/BSBMT 2013: "It is recommended that the diagnosis of veno-occlusive disease (sinusoidal obstruction syndrome) [VOD (SOS)] be based primarily on established clinical criteria (modified Seattle or Baltimore criteria) (1A)." The EBMT adult criteria keep the Baltimore requirement of bilirubin of 2 mg/dL or more for classical disease in the first 21 days, add late-onset disease after day 21, and since 2023 a probable category. The EBMT paediatric criteria drop both the time limit and the mandatory bilirubin and add transfusion-refractory thrombocytopenia.
Evidence: The EBMT Handbook says of the older definitions that "they were not suitable criteria for early diagnosis, and they missed late-onset SOS/VOD". For children it reports a single-centre comparison in which the modified Seattle criteria delayed diagnosis by a median of 3 days against the paediatric EBMT criteria. The EBMT severity grades were validated in 203 patients (Yoon 2019, as the Handbook reports). A third proposal (Cairo 2020) calls its criteria panel opinion: any two of a longer list of signs that includes bilirubin of 2 mg/dL or more, unexpected weight gain of 5% or more, refractory thrombocytopenia, hepatomegaly, right upper quadrant pain, ascites and reversed portal flow on ultrasound, or a liver biopsy consistent with the disease. Three of its four authors declared consultancy or research funding from the maker of defibrotide.
British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 · EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024 · EBMT (Bone Marrow Transplantation, Mohty et al.). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) 2016 · EBMT (Bone Marrow Transplantation, Mohty et al.). All authors declared honoraria or research support from Jazz Pharmaceuticals (industry) 2023 · EBMT (Bone Marrow Transplantation, Corbacioglu et al.). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry); all authors declared honoraria or research support from Jazz 2018 · British Journal of Haematology (Cairo, Cooke, Lazarus and Chao). Three authors declared consultancy, speaker or research funding from Jazz Pharmaceuticals (industry) 2020
Where it differs: Gives defibrotide at the treatment dose from the start of conditioning in people at high risk, rather than only once the disease appears (EBMT 2020 says until day 21 or earlier discharge; the paediatric trial gave it until day 30). BCSH/BSBMT 2013 recommends it in children having an allogeneic transplant with listed risk factors (1A) and suggests it in adults with the same risk factors (2B). EBMT 2020: "DF prophylaxis can be considered in adult patients at very high risk of SOS/VOD." EBMT's 2026 paediatric consensus uses a weighted risk score: prophylaxis not recommended below 3, advisable at 3, recommended at 4 or more.
Evidence: A paediatric randomised trial (2012) found the disease by day 30 in 22 of 180 children given defibrotide (12%) and 35 of 176 controls (20%); EBMT 2020 reports no significant fall in deaths from the disease by day 100 (2% against 6%). The HARMONY trial (372 children and adults at high or very high risk, stopped early for futility) found survival free of veno-occlusive disease by day 30 of 67% with defibrotide (190 patients) and 73% with best supportive care alone (182 patients), and concluded: "Defibrotide did not show a benefit in the prophylaxis of sinusoidal obstruction syndrome." The European Medicines Agency's communication to prescribers, sent in June 2022 on that trial's results, says: "Defitelio is not to be used as prophylaxis for VOD". The 2026 EBMT paediatric paper argues that the trial had design weaknesses, among them including patients with lower risk, and considers prophylaxis justified in high-risk children. The paediatric trial was funded by Gentium, the company that holds the European marketing authorisation, and EBMT; HARMONY by Jazz; EBMT 2020 had a Jazz educational grant; the 2026 paper declares no competing interests. Neither label's indication includes prevention.
British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 · EBMT task force (Bone Marrow Transplantation, Mohty et al.). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) 2020 · EBMT Paediatric Diseases Working Party (Bone Marrow Transplantation, Corbacioglu et al.). Declares no competing interests 2026 · The Lancet Haematology (Grupp et al.). Funded by Jazz Pharmaceuticals (industry). Two corrections were published in 2023 2023 · The Lancet (Corbacioglu et al.). Funded by Gentium SpA (industry) and the European Group for Blood and Marrow Transplantation 2012 · European Medicines Agency; the communication is issued by the marketing authorisation holder (industry) in agreement with the Agency 2023 · Jazz Pharmaceuticals (industry), on DailyMed, US National Library of Medicine 2025
Where it differs: The US label's indication is disease "with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT)", for a minimum of 21 days and up to 60. The European label's indication is "severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy", in adults and in children over 1 month of age, for at least 21 days and until the signs resolve. EBMT treats severe and very severe disease at once, advises early treatment of moderate disease, and watches mild disease closely; its 2020 statement allows stopping before 21 days if all signs have resolved, and the 2024 Handbook gives the duration as at least 14 to 21 days and until resolution.
Evidence: EBMT 2020 says the case for treating mild or moderate disease is less certain but cites expanded-access programmes in which earlier treatment after diagnosis went with higher survival at day 100. The Handbook: "we also recommend early initiation of defibrotide in patients with moderate SOS/VOD". BCSH/BSBMT 2013 recommends defibrotide for treatment in adults and children without a severity threshold (1B).
Jazz Pharmaceuticals (industry), on DailyMed, US National Library of Medicine 2025 · European Medicines Agency; the communication is issued by the marketing authorisation holder (industry) in agreement with the Agency 2023 · EBMT task force (Bone Marrow Transplantation, Mohty et al.). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) 2020 · EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024 · British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013
Where it differs: Adds methylprednisolone to treatment. The British guideline allows it to be considered; EBMT recommends against it as the sole prolonged treatment.
Evidence: BCSH/BSBMT 2013: "Methylprednisolone may be considered for use in the treatment of veno-occlusive disease with the appropriate caveats of caution regarding infection (2C)." EBMT 2020: "We therefore recommend against the use of methylprednisolone alone as a prolonged primary treatment of SOS/VOD", citing scarce, mainly retrospective data (one prospective study in 48 patients and small paediatric series), no defined dose and infection risk.
British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 · EBMT task force (Bone Marrow Transplantation, Mohty et al.). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) 2020
Where it differs: A 2025 UK consensus of 44 statements, agreed by 70 nurses, pharmacists and consultants, sets out how units should assess risk and monitor, for example: "VOD risk assessment should include the use of the online Center for International Blood and Marrow Transplant Research (CIBMTR) Risk Calculator".
Evidence: A modified Delphi survey, not a guideline. The paper states: "The study was initiated and funded by Jazz Pharmaceuticals." EBMT 2020 also mentions the CIBMTR score as an alternative way to identify high-risk patients.
EJHaem (Clark et al.). Initiated and funded by Jazz Pharmaceuticals (industry) 2025 · EBMT task force (Bone Marrow Transplantation, Mohty et al.). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) 2020
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Diagnosis based primarily on modified Seattle or Baltimore criteria | 1A | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Ultrasound may help exclude other disorders “Ultrasound imaging may be helpful in the exclusion of other disorders in patients with suspected VOD (SOS) (1C).” | 1C | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Liver biopsy by the transjugular approach “It is recommended that liver biopsies are undertaken using the transjugular approach in order to reduce the risks associated with the procedure (1C).” | 1C | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Ursodeoxycholic acid suggested for prophylaxis “Ursodeoxycholic acid is suggested for use in the prophylaxis of VOD (SOS) (2C).” | 2C | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Heparin not suggested for prophylaxis “Heparin (unfractionated and low molecular weight) is not suggested for use in the prophylaxis of VOD (SOS) due to the risk of increased toxicity (2B).” | 2B | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Pentoxifylline not recommended for prophylaxis “Pentoxifylline is not recommended in the prophylaxis of VOD (SOS) due to lack of efficacy (1A).” | 1A | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Prostaglandin E1 not recommended for prophylaxis “Prostaglandin E1 is not recommended in the prophylaxis of VOD (SOS) due to lack of efficacy and toxicity (1B).” | 1B | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Defibrotide recommended for treatment in adults and children “Defibrotide is recommended in the treatment of VOD (SOS) in adults and children (1B).” | 1B | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Tissue plasminogen activator not recommended for treatment “Tissue plasminogen activator is not recommended for use in the treatment of VOD (SOS) due to the associated risk of haemorrhage (1B).” | 1B | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Judicious fluid balance management “Judicious clinical care, particularly in the management of fluid balance, is recommended in the management of VOD (SOS) (1C).” | 1C | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Defibrotide dose of 25 mg/kg a day recommended by EBMT “Therefore, the dose approved by the FDA and the EMA, and which we recommend, is 25 mg/kg/day.” | Expert position (ungraded) | EBMT task force (Bone Marrow Transplantation, Mohty et al.). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) 2020 |
| Defibrotide prophylaxis did not improve survival free of veno-occlusive disease by day 30 in HARMONY “Defibrotide did not show a benefit in the prophylaxis of sinusoidal obstruction syndrome.” | Randomised phase 3 trial, stopped for futility | The Lancet Haematology (Grupp et al.). Funded by Jazz Pharmaceuticals (industry). Two corrections were published in 2023 2023 |
| Defibrotide not recommended for prophylaxis by the European Medicines Agency “In view of these results and taking the safety profile into account, Defitelio is not recommended to be used as prophylaxis of VOD.” | Regulator's communication to prescribers (ungraded) | European Medicines Agency; the communication is issued by the marketing authorisation holder (industry) in agreement with the Agency 2023 |
Shares Defibrotide, Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure, Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation.
Shares Caution: inotuzumab before transplant (veno-occlusive disease), Inotuzumab ozogamicin, Allogeneic stem cell transplantation.
Shares GVHD prophylaxis after allogeneic stem cell transplant: choosing the regimen, Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation.
Shares GVHD prophylaxis after allogeneic stem cell transplant: choosing the regimen, Conditioning regimen (myeloablative, reduced-intensity), Allogeneic stem cell transplantation.
Shares Conditioning regimen (myeloablative, reduced-intensity), Allogeneic stem cell transplantation.